Related Experiment Video
Updated: Dec 31, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206)
1Division of Hematology-Oncology, 11-934 Factor Building. UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, California 90095-1782, USA. aribas@mednet.ucla.edu
Abstract:
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade therapies have been evaluated in clinical trials and have shown promise as possible options for treating patients with cancer. One agent under investigation is tremelimumab (CP-675,206), a monoclonal antibody that has been demonstrated to be a safe and efficacious treatment in patients with malignant melanoma. Results of a phase I clinical trial suggested that a dose of 15 mg/kg of tremelimumab would be the maximum-tolerated dose, with the most common grade 3-4 toxicities being diarrhea and rash. Pharmacokinetic studies showed that the postinfusion plasma concentration and area under the plasma disposition curve both increased in an approximately proportional manner with dose. Studies also showed that tremelimumab has a low clearance (0.132 ml/h x kg), a small volume of distribution (81.2 ml/kg), and a long terminal-phase half-life (22.1 days). A pivotal phase II clinical trial assessing single-agent tremelimumab as second-line therapy in metastatic melanoma has completed accrual, with response rate as the primary endpoint. A pivotal phase III trial has also completed accrual; that study compared the overall survival of previously untreated patients receiving single-agent tremelimumab versus dacarbazine or temozolomide.
Insights
Tremelimumab, a CTLA-4 blockade therapy, shows promise for cancer treatment, particularly in malignant melanoma. Clinical trials indicate its safety and efficacy, with ongoing studies evaluating its impact on overall survival.
Area of Science:
- Immunotherapy
- Oncology
- Pharmacology
Background:
- Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade therapies are emerging as potential cancer treatments.
- Tremelimumab is a monoclonal antibody investigated for its therapeutic potential.
Purpose of the Study:
- To evaluate the safety and efficacy of tremelimumab in patients with malignant melanoma.
- To determine the maximum-tolerated dose and pharmacokinetic profile of tremelimumab.
- To assess tremelimumab's efficacy as a single agent in metastatic melanoma and compare its overall survival benefit against standard chemotherapy.
Main Methods:
- Phase I clinical trial to establish maximum-tolerated dose and safety profile.
- Pharmacokinetic studies to analyze drug disposition (clearance, volume of distribution, half-life).
- Phase II and III clinical trials assessing response rate and overall survival in metastatic melanoma patients.
Main Results:
- The maximum-tolerated dose of tremelimumab was determined to be 15 mg/kg.
- Common severe toxicities (grade 3-4) included diarrhea and rash.
- Pharmacokinetic studies revealed dose-proportional increases in plasma concentration and area under the curve, with low clearance and a long half-life.
- Phase II and III trials in metastatic melanoma have completed accrual for response rate and overall survival assessments, respectively.
Conclusions:
- Tremelimumab demonstrates a favorable safety profile and pharmacokinetic properties for cancer therapy.
- Ongoing clinical trials are crucial for establishing tremelimumab's role in treating malignant melanoma, particularly in comparison to existing chemotherapies.
